Hennion & Walsh Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.02M | Buy |
140,121
+9,060
| +7% | +$195K | 0.12% | 218 |
|
|
2025
Q1 | $2.18M | Buy |
131,061
+27,736
| +27% | +$461K | 0.1% | 254 |
|
|
2024
Q4 | $1.9M | Buy |
103,325
+7,491
| +8% | +$137K | 0.09% | 301 |
|
|
2024
Q3 | $1.47M | Sell |
95,834
-6,643
| -6% | -$102K | 0.07% | 361 |
|
|
2024
Q2 | $1.67M | Sell |
102,477
-40,521
| -28% | -$658K | 0.09% | 293 |
|
|
2024
Q1 | $2.64M | Buy |
142,998
+27,871
| +24% | +$515K | 0.14% | 201 |
|
|
2023
Q4 | $3.6M | Sell |
115,127
-24,912
| -18% | -$780K | 0.21% | 127 |
|
|
2023
Q3 | $2.92M | Sell |
140,039
-11,068
| -7% | -$231K | 0.19% | 134 |
|
|
2023
Q2 | $3.62M | Sell |
151,107
-60,670
| -29% | -$1.45M | 0.21% | 116 |
|
|
2023
Q1 | $3.99M | Buy |
211,777
+3,028
| +1% | +$57K | 0.24% | 102 |
|
|
2022
Q4 | $3.32M | Buy |
208,749
+8,717
| +4% | +$139K | 0.21% | 129 |
|
|
2022
Q3 | $3.27M | Buy |
200,032
+2,117
| +1% | +$34.6K | 0.22% | 123 |
|
|
2022
Q2 | $2.79M | Sell |
197,915
-13,577
| -6% | -$191K | 0.17% | 154 |
|
|
2022
Q1 | $5.12M | Buy |
211,492
+21,337
| +11% | +$517K | 0.27% | 95 |
|
|
2021
Q4 | $4.44M | Buy |
190,155
+8,692
| +5% | +$203K | 0.22% | 126 |
|
|
2021
Q3 | $3.01M | Buy |
181,463
+13,364
| +8% | +$222K | 0.16% | 188 |
|
|
2021
Q2 | $4.1M | Buy |
168,099
+8,975
| +6% | +$219K | 0.22% | 118 |
|
|
2021
Q1 | $4.11M | Buy |
+159,124
| New | +$4.11M | 0.25% | 105 |
|